Onesource Specialty Pharma delivered a remarkable financial turnaround in Q1 FY27, reporting a consolidated net profit of ₹25 crore for the quarter ended June 30, 2026, compared with a net loss of ₹2 million in the corresponding quarter of the previous fiscal year. According to reports from Business Standard, the company's profit before exceptional items and tax reached ₹24.59 crore during the quarter, marking a significant improvement from the loss of ₹1.52 crore recorded in Q1 FY26. The strong performance was driven by commercial supplies of generic semaglutide leading to impressive growth across key metrics. However, the consolidated group turned profitable with a net profit of ₹25 crore, though subsidiary performance dragged consolidated earnings down by ₹26.23 crore, as reported by The Economic Times. The Board of Directors approved the unaudited financial results on July 24, 2026, following a limited review by statutory auditors Deloitte Haskins & Sells.
The company's revenue from operations increased 37% year-on-year to ₹4,490 crore in Q1 FY27, up from ₹3,273 crore in Q1 FY26, as reported by Business Standard. This growth was primarily driven by the commercial launch of semaglutide, new master service agreement contracts, and customer wins across its business segments. The company also recorded an exceptional loss of ₹4.30 crore during the quarter due to legal charges related to legacy litigation involving employees of a subsidiary. The Economic Times reports that standalone revenue from operations grew approximately 39.52% YoY to ₹4,465 crore, with the company transitioning from a pre-approval phase to a strong commercial revenue phase backed by successful generic semaglutide launches in Canada and India. The adjusted PAT surged 72% to ₹637 million, reflecting strong operational leverage from the commercialisation of semaglutide products in Canada and India, alongside new customer wins in its biologics business.
According to Business Standard, Onesource Specialty Pharma achieved strong operational performance with EBITDA standing at ₹1,233 crore, registering 39% year-on-year growth. The EBITDA margin improved to 27.5% in Q1 FY27 compared to 27% in Q1 FY26, demonstrating enhanced operational efficiency. The 39% surge in EBITDA outpacing the 37% revenue growth indicates improving operating leverage as higher-margin semaglutide sales scale. The expansion of EBITDA margins by 43 basis points year-on-year, despite inflationary pressures, suggests effective cost management and product mix optimisation. The company's standalone EBITDA increased approximately 37.84% YoY to ₹110 crore, with standalone EBITDA margin expanding by approximately 65 basis points YoY to 25.53%, as reported by The Economic Times. The strong operational performance was driven by the company's multi-modality CDMO model, especially benefiting from the global semaglutide (GLP-1) opportunity and complex injectables commercialization.
The company is on the verge of completing its phase 1 expansion, which will double fill-finish capacity, with further additions to be completed by the end of FY27, as reported by ICICI Securities. The Economic Times reports that the second cartridge line is expected to commence commercial operations in Q2 FY27, supporting the company's growth trajectory. Onesource Specialty Pharma has started enrolling new customers for GLP-1 and has decent order book visibility to meet its FY28 revenue and EBITDA guidance of USD 400mn and USD 160mn, respectively. The company has committed 80% of its announced $100 million capex program for Phase 2 expansion, which will triple sterile production days by FY28 through Line 1 installation. The company's biologics segment is emerging as a new growth catalyst, with recent client empanelment expected to aid material growth starting in FY29. Looking ahead, the company reiterated its FY28 guidance, targeting $400 million in organic revenue and an EBITDA margin of 40%, reflecting confidence in its long-term growth trajectory.
ICICI Securities has issued a buy rating on Onesource Specialty Pharma with a target price of ₹2,400 in its research report dated July 26, 2026. The brokerage raised FY28E EPS by ~9% to account for the ramp-up in DDC capacities and currency benefits. The recommendation reflects confidence in the company's strong operational performance, capacity expansion plans, and robust order book visibility supporting its ambitious growth targets. However, investors will closely watch the progression of subsidiary performance to see if the consolidated drag eases in coming quarters, as reported by The Economic Times. The ultimate investment thesis relies on management's ability to clean up subsidiary losses and navigate the ongoing USD 136.32 million Sputnik vaccine legal claim with Prestige Biopharma successfully. The divergence between standalone PAT (₹512 million) and adjusted consolidated PAT (₹637 million) illustrates the impact of inter-company eliminations and specific accounting treatments for scheme-related intangibles.
